Shanghai Hile Bio-tech
Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The In Vitro Diagnostic Reagents segment offers biochemical diagnostic reagents, immuno-latex reagents, immune turbidimetry… Read more
Shanghai Hile Bio-tech (603718) - Total Assets
Latest total assets as of September 2025: CN¥1.80 Billion CNY
Based on the latest financial reports, Shanghai Hile Bio-tech (603718) holds total assets worth CN¥1.80 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shanghai Hile Bio-tech - Total Assets Trend (2011–2024)
This chart illustrates how Shanghai Hile Bio-tech’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shanghai Hile Bio-tech - Asset Composition Analysis
Current Asset Composition (December 2024)
Shanghai Hile Bio-tech's total assets of CN¥1.80 Billion consist of 37.9% current assets and 62.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 19.6% |
| Accounts Receivable | CN¥111.89 Million | 6.1% |
| Inventory | CN¥55.01 Million | 3.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥55.58 Million | 3.0% |
| Goodwill | CN¥1.01 Billion | 55.1% |
Asset Composition Trend (2011–2024)
This chart illustrates how Shanghai Hile Bio-tech's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Hile Bio-tech's current assets represent 37.9% of total assets in 2024, a decrease from 48.6% in 2011.
- Cash Position: Cash and equivalents constituted 19.6% of total assets in 2024, down from 40.2% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 58.0% of total assets, an increase from 6.0% in 2011.
- Asset Diversification: The largest asset category is goodwill at 55.1% of total assets.
Shanghai Hile Bio-tech Competitors by Total Assets
Key competitors of Shanghai Hile Bio-tech based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Shanghai Hile Bio-tech - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Shanghai Hile Bio-tech generates 0.15x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Shanghai Hile Bio-tech generates $9.37 in net profit.
Shanghai Hile Bio-tech - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.63 | 3.15 | 1.16 |
| Quick Ratio | 6.92 | 2.92 | 0.98 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥568.13 Million | CN¥ 798.75 Million | CN¥ 102.48 Million |
Shanghai Hile Bio-tech - Advanced Valuation Insights
This section examines the relationship between Shanghai Hile Bio-tech's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.06 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | 10.2% |
| Total Assets | CN¥1.83 Billion |
| Market Capitalization | $234.31 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Hile Bio-tech's assets below their book value (0.13 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Shanghai Hile Bio-tech's assets grew by 10.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Shanghai Hile Bio-tech (2011–2024)
The table below shows the annual total assets of Shanghai Hile Bio-tech from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.83 Billion | +10.20% |
| 2023-12-31 | CN¥1.66 Billion | +9.48% |
| 2022-12-31 | CN¥1.51 Billion | -17.89% |
| 2021-12-31 | CN¥1.84 Billion | +3.21% |
| 2020-12-31 | CN¥1.79 Billion | +5.02% |
| 2019-12-31 | CN¥1.70 Billion | -2.70% |
| 2018-12-31 | CN¥1.75 Billion | +9.17% |
| 2017-12-31 | CN¥1.60 Billion | +8.23% |
| 2016-12-31 | CN¥1.48 Billion | +19.32% |
| 2015-12-31 | CN¥1.24 Billion | +89.51% |
| 2014-12-31 | CN¥654.48 Million | +8.93% |
| 2013-12-31 | CN¥600.84 Million | +7.17% |
| 2012-12-31 | CN¥560.66 Million | +11.23% |
| 2011-12-31 | CN¥504.03 Million | -- |